SCHEMBL15067966

SCHEMBL15067966

CCN(CC)S(=O)(=O)c1cnc(OCC2CC2)c(Br)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.53
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CCNA1 P78396 1/20 0.46
ALDH1A1 P00352 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 2/20 0.41
LMNA P02545 4/20 0.40
TSHR P16473 4/20 0.40
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
HPGD P15428 1/20 0.37
CNR2 P34972 1/20 0.36
HTT P42858 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16651408 0.83 BRD4 (0.41) BRD4CCNA2CDK2CCNA1CNR2
SCHEMBL15067934 0.83 BRD4 (0.47) BRD4CCNA2CDK2CCNA1CNR2
SCHEMBL31454315 0.81 ALDH1A1 (0.52) ALDH1A1NPSR1MAPTLMNATSHR
SCHEMBL31454311 0.77 ALDH1A1 (0.49) ALDH1A1NPSR1MAPTLMNATSHR
SCHEMBL1700092 0.75 BRD4 (0.47) BRD4CCNA2CDK2CCNA1ALDH1A1
SCHEMBL15646631 0.75 IDH2 (0.47) BRD4ALDH1A1
SCHEMBL1958924 0.74 ATXN2 (0.42) BRD4CCNA2CDK2CCNA1
SCHEMBL16650762 0.73 BRD4 (0.42) BRD4CCNA2CDK2CCNA1CNR2
SCHEMBL1957468 0.73 BRD4 (0.43) BRD4CCNA2CDK2CCNA1CNR2
SCHEMBL1957471 0.73 BRD4 (0.43) BRD4CCNA2CDK2CCNA1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 US disclosed
US-20210236508-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2021-08-05 US disclosed
US-20180296566-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2018-10-18 US disclosed
EP-2797918-B1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2017-11-29 EP disclosed
US-20160143916-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2016-05-26 US disclosed
US-9296741-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2797918-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2014-11-05 EP disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180296566-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 BRD4 1/4885CCNA2 54/4885CDK2 48/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 BRD4 1/4885CCNA2 54/4885CDK2 48/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 BRD4 1/4885CCNA2 54/4885CDK2 48/4885
US-20160143916-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 BRD4 1/4885CCNA2 54/4885CDK2 48/4885
US-20210236508-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 BRD4 1/4885CCNA2 54/4885CDK2 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.